Molecular Oncology
Volume 4, Issue 1 , Pages 65-89 , February 2010

Up-regulated Proteins in the Fluid Bathing the Tumour Cell Microenvironment as Potential Serological Markers for Early Detection of Cancer of the Breast

  • Pavel Gromov

      Affiliations

    • Institute of Cancer Biology, Danish Cancer Society, DK-2100 Copenhagen, Denmark
    • The Danish Centre for Translational Breast Cancer Research, DK-2100 Copenhagen, Denmark
    • Corresponding Author InformationCorresponding authors. Institute of Cancer Biology and The Danish Centre for Translational Breast Cancer Research, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. Tel.: +45 35 257 354; fax: +45 35 257 363.
    • ,
  • Irina Gromova

      Affiliations

    • Institute of Cancer Biology, Danish Cancer Society, DK-2100 Copenhagen, Denmark
    • The Danish Centre for Translational Breast Cancer Research, DK-2100 Copenhagen, Denmark
    • ,
  • Jakob Bunkenborg

      Affiliations

    • Department of Biochemistry and Molecular Biology, University of Southern Denmark, DK-5230 Odense, Denmark
    • ,
  • Teresa Cabezon

      Affiliations

    • Institute of Cancer Biology, Danish Cancer Society, DK-2100 Copenhagen, Denmark
    • The Danish Centre for Translational Breast Cancer Research, DK-2100 Copenhagen, Denmark
    • ,
  • José M.A. Moreira

      Affiliations

    • Institute of Cancer Biology, Danish Cancer Society, DK-2100 Copenhagen, Denmark
    • The Danish Centre for Translational Breast Cancer Research, DK-2100 Copenhagen, Denmark
    • ,
  • Vera Timmermans-Wielenga

      Affiliations

    • Department of Pathology, The Centre of Diagnostic Investigations, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark
    • The Danish Centre for Translational Breast Cancer Research, DK-2100 Copenhagen, Denmark
    • ,
  • Peter Roepstorff

      Affiliations

    • Department of Biochemistry and Molecular Biology, University of Southern Denmark, DK-5230 Odense, Denmark
    • ,
  • Fritz Rank

      Affiliations

    • Institute of Cancer Biology, Danish Cancer Society, DK-2100 Copenhagen, Denmark
    • Department of Pathology, The Centre of Diagnostic Investigations, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark
    • The Danish Centre for Translational Breast Cancer Research, DK-2100 Copenhagen, Denmark
    • ,
  • Julio E. Celis

      Affiliations

    • Institute of Cancer Biology, Danish Cancer Society, DK-2100 Copenhagen, Denmark
    • The Danish Centre for Translational Breast Cancer Research, DK-2100 Copenhagen, Denmark
    • Corresponding Author InformationCorresponding authors. Institute of Cancer Biology and The Danish Centre for Translational Breast Cancer Research, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. Tel.: +45 35 257 354; fax: +45 35 257 363.

Received 1 November 2009 ,Revised 13 November 2009 ,Accepted 13 November 2009.

References 

  1. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003;422:198–207
  2. Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A. Correlation of serum and salivary CA15-3 levels in patients with breast cancer. Med. Oral. Patol. Oral. Cir. Bucal. 2009;14:e521–e524
  3. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell. Proteomics. 2004;3:311–326
  4. Anderson NL, Anderson NG, Pearson TW, Borchers CH, Paulovich AG, Patterson SD, et al. A human proteome detection and quantitation project. Mol. Cell. Proteomics. 2009;8:883–886
  5. Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D, et al. Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin. Chem. Lab. Med. 2009;47:724–744
  6. Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M, et al. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis. 1997;18:2832–2841
  7. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72:248–254
  8. Brenner J, Sawant SG, Hande MP, Miller RC, Elliston CD, Fu Z, et al. Routine screening mammography: how important is the radiation-risk side of the benefit-risk equation?. Int. J. Radiat. Biol. 2002;78:1065–1067
  9. Brooks M. Breast cancer screening and biomarkers. Methods Mol. Biol. 2009;472:307–321
  10. Casiano CA, Mediavilla-Varela M, Tan EM. Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol. Cell. Proteomics. 2006;5:1745–1759
  11. Celis JE, Ratz GP, Celis A. Secreted proteins from normal and SV40 transformed human MRC-5 fibroblasts: toward establishing a database of human secreted proteins. Leukemia. 1987;1:707–717
  12. Celis JE, Ratz GP, Madsen P, Gesser B, Lauridsen JB, Hansen KP, et al Computerized, comprehensive databases of cellular and secreted proteins from normal human embryonic lung MRC-5 fibroblasts: identification of transformation and/or proliferation sensitive proteins. Electrophoresis. 1989;10:76–115
  13. Celis JE, Ostergaard M, Basse B, Celis A, Lauridsen JB, Ratz GP, et al. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res. 1996;56:4782–4790
  14. Celis A, Rasmussen HH, Celis P, Basse B, Lauridsen JB, Ratz G, et al. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis. 1999;20:355–361
  15. Celis JE, Gromov P, Cabezón T, Moreira JM, Ambartsumian N, Sandelin K, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics. 2004;3:327–344
  16. Celis JE, Moreira JM, Cabezón T, Gromov P, Friis E, Rank F, et al. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol. Cell. Proteomics. 2005;4:492–522
  17. Celis JE, Trentemølle S, Gromov P. Gel-based proteomics: high-resolution two-dimensional gel electrophoresis of proteins. Isoelectric focusing (IEF) and nonequilibrium pH gradient electrophoresis (NEPHGE). In:  Celis JE,  Carter N,  Hunter T,  Shotton D,  Simons K,  Small JV editor. Cell Biology. A Laboratory Handbook. 4:San Diego, CA: Elsevier; 2005;p. 165–177
  18. Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans-Wielenga V, et al. Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol. Oncol. 2007;1:321–349
  19. Celis JE, Moreira JM, Gromova I, Cabezón T, Gromov P, Shen T, et al. Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol. Oncol. 2007;1:97–119
  20. Celis JE, Gromov P, Cabezón T, Moreira JM, Friis E, Jirström K, et al. 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. Mol. Cell. Proteomics. 2008;7:1795–1809
  21. Celis, J.E., Cabezón, T., Moreira, J.M., Gromov, P., Gromova, I., Timmermans-Wielenga, V., Iwase, T., Akiyama, F., Honma, N., Rank, F., 2009. Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a well-defined cohort. Mol. Oncol. Feb 3. [Epub ahead of print].
  22. Chahed K, Kabbage M, Hamrita B, Guillier CL, Trimeche M, Remadi S, et al. Detection of protein alterations in male breast cancer using two dimensional gel electrophoresis and mass spectrometry: the involvement of several pathways in tumorigenesis. Clin. Chim. Acta. 2008;388:106–114
  23. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann. Oncol. 2007;18:868–873
  24. Chen EI, Yates JR. Cancer proteomics by quantitative shotgun proteomics. Mol. Oncol. 2007;1:144–159
  25. Conrotto P, Souchelnytskyi S. Proteomic approaches in biological and medical sciences: principles and applications. Exp. Oncol. 2008;30:171–180
  26. Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands JL, et al. Urine in clinical proteomics. Mol. Cell. Proteomics. 2008;7:1850–1862
  27. Dede DS, Arslan C, Altundag K. Serum levels of CEA and CA 15-3 in triple-negative breast cancer at the time of diagnosis. Med. Oncol. 2009;Sep 23. [Epub ahead of print]
  28. Deng SS, Xing TY, Zhou HY, Xiong RH, Lu YG, Wen B, et al. Comparative proteome analysis of breast cancer and adjacent normal breast tissues in human. Genom. Proteom. Bioinform. 2006;4:165–172
  29. Desmetz C, Bascoul-Mollevi C, Rochaix P, Lamy P-J, Kramar A, Rouanet P, et al. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin. Cancer Res. 2009;15:4733–4741
  30. Doustjalali SR, Yusof R, Yip CH, Looi LM, Pillay B, Hashim OH. Aberrant expression of acute-phase reactant proteins in sera and breast lesions of patients with malignant and benign breast tumors. Electrophoresis. 2004;25:2392–2401
  31. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value?. Clin. Chem. 2006;52:345–351
  32. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA. 2005;293:1245–1256
  33. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–410
  34. Faça VM, Ventura AP, Fitzgibbon MP, Pereira-Faça SR, Pitteri SJ, Green AE, et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One. 2008;3(6):e2425
  35. Fass L. Imaging and cancer: a review. Mol. Oncol. 2008;2:115–152
  36. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 2007;18:581–592
  37. Franzén B, Linder S, Alaiya AA, Eriksson E, Fujioka K, Bergman AC, et al. Analysis of polypeptide expression in benign and malignant human breast lesions. Electrophoresis. 1997;18:582–587
  38. Gagnon A, Shi Q, Ye B. Surface-enhanced laser desorption/ionization mass spectrometry for protein and Peptide profiling of body fluids. Methods Mol. Biol. 2008;441:41–56
  39. Garrisi VM, Abbate I, Quaranta M, Mangia A, Tommasi S, Paradiso A. SELDI-TOF serum proteomics and breast cancer: which perspective?. Expert Rev. Proteomics. 2008;5:779–785
  40. Gast MC, van Dulken EJ, van Loenen TK, Kingma-Vegter F, Westerga J, Flohil CC, et al. Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling. Int. J. Biol. Markers. 2009;24:130–141
  41. Gast MC, Van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, et al. Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. Oncol Rep. 2009;22:205–213
  42. Gillet D, Kennedy C, Carmalt H. Breast cancer in young women. Aust. N.Z.J. Surg. 1997;67:761–764
  43. Gion M, Mione R, Leon AE, Lüftner D, Molina R, Possinger K, et al. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur. J. Cancer. 2001;37:355–363
  44. Gonçalves A, Charafe-Jauffret E, Bertucci F, Audebert S, Toiron Y, Esterni B, et al. Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol. Cell. Proteomics. 2008;7:1420–1433
  45. Gromov P, Celis JE, Gromova I, Rank F, Timmermans-Wielenga V, Moreira JM. A single lysis solution for the analysis of tissue samples by different proteomic technologies. Mol. Oncol. 2008;2:368–379
  46. Gromova I, Celis JE. Protein detection in gels by silver staining: a procedure compatible with mass-spectrometry. In:  Celis JE,  Carter N,  Hunter T,  Shotton D,  Simons K,  Small JV editor. Cell Biology. A Laboratory Handbook. vol. 4:San Diego: Academic Press; 2006;p. 219–223
  47. Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J. Neurooncol. 2009;94:229–234
  48. Haab BB. Antibody arrays in cancer research. Mol. Cell. Proteomics. 2005;4:377–383
  49. Hamrita B, Chahed K, Kabbage M, Guillier CL, Trimeche M, Chaïeb A, et al. Identification of tumor antigens that elicit a humoral immune response in breast cancer patients’ sera by serological proteome analysis (SERPA). Clin. Chim. Acta. 2008;393:95–102
  50. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452:571–579
  51. Harter C, Reinhard C. The secretory pathway from history to the state of the art. Subcell Biochem. 2000;34:1–38
  52. Hayes DF. Serum (circulating) tumor markers for breast cancer. Recent Results Cancer Res. 1996;140:101–113
  53. Hegmans JP, Bard MP, Hemmes A, Luider TM, Willemsen R, Severijnen LA, et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am. J. Pathol. 2004;164:1807–1815
  54. Honma N, Takubo K, Akiyama F, Sawabe M, Arai T, Younes M, et al. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology. 2005;47:195–201
  55. Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. Proteomics. 2006;6:6326–6353
  56. Huang R, Lin Y, Shi Q, Flowers L, Ramachandran S, Horowitz IR, et al. Enhanced protein profiling arrays with ELISA-based amplification for high-throughput molecular changes of tumor patients’ plasma. Clin. Cancer Res. 2004;10:598–609
  57. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2002;137:347–360
  58. Issaq HJ, Xiao Z, Veenstra TD. Serum and plasma proteomics. Chem. Rev. 2007;107:3601–3620
  59. Jacobs JM, Waters KM, Kathmann LE, Camp DG, Wiley HS, Smith RD, et al. The mammary epithelial cell secretome and its regulation by signal transduction pathways. J. Proteome Res. 2008;7:558–569
  60. Jeffery J, Murphy MJ. Ascitic fluid analysis: the role of biochemistry and haematology. Hosp. Med. 2001;62:282–286
  61. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 2007;1:84–96
  62. Kilic A, Schuchert MJ, Luketich JD, Landreneau RJ, Lokshin AE, Bigbee WL, et al. Use of novel autoantibody and cancer-related protein arrays for the detection of esophageal adenocarcinoma in serum. Thorac. Cardiovasc. Surg. 2008;136:199–204
  63. Kim HS, Park YH, Park MJ, Chang MH, Jun HJ, Kim KH, et al. Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res. Treat. 2009;118:89–97
  64. Koga K, Matsumoto K, Akiyoshi T, Kubo M, Yamanaka N, Tasaki A, et al. Purification, characterization and biological significance of tumor-derived exosomes. Anticancer Res. 2005;25:3703–3707
  65. Kulasingam V, Diamandis EP. Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol. Cell. Proteomics. 2007;6:1997–2011
  66. Kulasingam V, Diamandis EP. Tissue culture-based breast cancer biomarker discovery platform. Int. J. Cancer. 2008;123:2007–2012
  67. Liang X, Huuskonen J, Hajivandi M, Manzanedo R, Predki P, Amshey JR, et al. Identification and quantification of proteins differentially secreted by a pair of normal and malignant breast-cancer cell lines. Proteomics. 2009;9:182–193
  68. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411:375–379
  69. Liu X, Feng Q, Chen Y, Zuo J, Gupta N, Chang Y, et al. Proteomics-based identification of differentially-expressed proteins including galectin-1 in the blood plasma of type 2 diabetic patients. J. Proteome Res. 2009;8:1255–1262
  70. Loch CM, Ramirez AB, Liu Y, Sather CL, Delrow JJ, Scholler N, et al. Use of high density antibody arrays to validate and discover cancer serum biomarkers. Mol. Oncol. 2007;1:313–320
  71. Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J. Proteome Res. 2008;7:1388–1394
  72. Lumachi F, Basso SM. Serum tumor markers in patients with breast cancer. Expert Rev. Anticancer Ther. 2004;4:921–931
  73. Lunt SJ, Fyles A, Hill RP, Milosevic M. Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis. Future Oncol. 2008;4:793–802
  74. Mannello F, Medda V, Tonti GA. Protein profile analysis of the breast microenvironment to differentiate healthy women from breast cancer patients. Expert Rev. Proteomics. 2009;6:43–60
  75. Martín A, Corte MD, Alvarez AM, Rodriguez JC, Andicoechea A, Bongera M, et al. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer. Anticancer Res. 2006;26:3965–3971
  76. Maurya P, Meleady P, Dowling P, Clynes M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res. 2007;27:1247–1255
  77. Mbeunkui F, Metge BJ, Shevde LA, Pannell LK. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J. Proteome Res. 2007;6:2993–3002
  78. Moreira JM, Ohlsson G, Rank FE, Celis JE. Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. Mol. Cell. Proteomics. 2005;4:555–569
  79. Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Sub-cellular Biochem. 1998;31:205–262
  80. Musselman I, Speicher DW. Human serum and plasma proteomics. Curr. Protoc. Protein Sci. 2005;Chapter 24, unit 24.1
  81. Nickel W. The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. Eur. J. Biochem. 2003;270:2109–2119
  82. Nothacker M, Duda V, Hahn M, Warm M, Degenhardt F, Madjar H, et al. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review. BMC Cancer. 2009;9:335
  83. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 1975;250:4007–4021
  84. Okano T, Kondo T, Kakisaka T, Fujii K, Yamada M, Kato H, et al. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics. 2006;6:3938–3948
  85. Oliver C, Vidal M. Proteomic analysis of secreted exosomes. Subcell. Biochem. 2007;43:99–131
  86. Omenn GS. Advancement of biomarker discovery and validation through the HUPO plasma proteome project. Dis. Markers. 2004;20:131–134
  87. Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat. Chem. Biol. 2005;1:252–262
  88. Paliouras M, Diamandis EP. Androgens act synergistically to enhance estrogen-induced upregulation of human tissue kallikreins 10, 11, and 14 in breast cancer cells via a membrane bound androgen receptor. Mol. Oncol. 2008;1:413–424
  89. Pan C, Kumar C, Bohl S, Klingmueller U, Mann M. Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol. Cell. Proteomics. 2009;8:443–450
  90. Pisano E. Issues in breast cancer screening. Technol. Cancer Res. Treat. 2005;4:5–9
  91. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomarker Insights. 2006;1:1–48
  92. Puntmann VO. How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgrad. Med. J. 2009;85:538–545
  93. Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, et al. Occurrence of autoantibodies to annexin I, 14-3-3 θ and LAMR1 in prediagnostic lung cancer sera. J. Clin. Oncol. 2008;26:5060–5066
  94. Rajcevic U, Niclou SP, Jiminez CR. Proteomics strategies for target identification and biomarker discovery in cancer. Front. Biosci. 2009;14:3292–3303
  95. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology. 2009;41:40–47
  96. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006;24:971–983
  97. Rose K, Bougueleret L, Baussant T, Böhm G, Botti P, Colinge J, et al. Industrial-scale proteomics: from liters of plasma to chemically synthesized proteins. Proteomics. 2004;4:2125–2150
  98. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320–368
  99. Rui Z, Jian-Guo J, Yuan-Peng T, Hai P, Bing-Gen R. Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics. 2003;3:433–439
  100. Schenk S, Schoenhals GJ, de Souza G, Mann M. A high confidence, manually validated human blood plasma protein reference set. BMC Med. Genomics. 2008;1:41
  101. Schiess R, Wollscheid B, Aebersold R. Targeted proteomic strategy for clinical biomarker discovery. Mol. Oncol. 2009;3:33–44
  102. Schmidt A, Aebersold R. High-accuracy proteome maps of human body fluids. Genome Biol. 2006;7:242
  103. Shen Y, Jacobs JM, Camp DG, Fang R, Moore RJ, Smith RD, et al. Ultra-high-efficiency strong cation exchange LC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome. Anal. Chem. 2004;76:1134–1344
  104. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996;68:850–858
  105. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert. Rev. Proteomics. 2009;6:267–283
  106. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  107. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA. 2001;98:10869–10874
  108. Souchelnytskyi S, Lomnytska M, Dubrovska A, Hellman U, Volodko N. Proteomics success story. Towards early detection of breast and ovarian cancer: plasma proteomics as a tool to find novel markers. Proteomics. 2006;6(Suppl. 2):65–68
  109. Stahl-Zeng J, Lange V, Ossola R, Eckhardt K, Krek W, Aebersold R, et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol. Cell. Proteomics. 2007;6:1809–1817
  110. Stefani MM, Guerra JG, Sousa AL, Costa MB, Oliveira ML, Martelli CT, et al. Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report. BMC Infect. Dis. 2009;9:75
  111. Takahashi T, Takasaki Y, Takeuchi K, Yamanaka K, Oshimi K, Hashimoto H. Detection of proliferating cell nuclear antigen (PCNA) in peripheral blood mononuclear cells and sera of patients with malignant lymphoma. Leuk. Lymphoma. 1997;28:113–125
  112. Timins JK. Controversies in mammography. N.J. Med. 2005;102:45–49
  113. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 2006;1:119–150
  114. Tracy RP, Currie RM, Young DS. Two-dimensional gel electrophoresis of serum specimens from a normal population. Clin. Chem. 1982;28:890–899
  115. Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int. J. Clin. Oncol. 2008;13:447–451
  116. Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS. Biomarkers: mining the biofluid proteome. Mol. Cell. Proteomics. 2005;4:409–418
  117. Witz IP. The tumor microenvironment: the making of a paradigm. Cancer Microenviron. 2009;2(Suppl. 1):9–17
  118. Xue H, Lu B, Lai M. The cancer secretome: a reservoir of biomarkers. J. Transl. Med. 2008;6:52
  119. Yom CK, Woo HY, Min SY, Kang SY, Kim HS. Clusterin overexpression and relapse-free survival in breast cancer. Anticancer Res. 2009;29:3909–3912
  120. Zeng Z, Hincapie M, Haab BB, Hanash S, Pitteri SJ, Kluck S, et al. The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. J. Chromatogr. A. 2009;Epub ahead of print
  121. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol. Cell. Proteomics. 2005;4:1686–1696

PII: S1574-7891(09)00140-9

doi: 10.1016/j.molonc.2009.11.003

Molecular Oncology
Volume 4, Issue 1 , Pages 65-89 , February 2010

Article Tools

* Image Usage & Resolution